Internal Medicine, Infectious Disease · Jacksonville, FL
NPI
1245347004
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
5
Medicare group memberships
Hospitals
1
Hospital affiliations
6817 Southpoint Pkwy Ste 801
Jacksonville, FL, 32216
Phone (904) 646-3420
Groups this clinician bills Medicare through
Medicare paid, 2024
$189K
2,530 services
Medicare patients, 2024
501
Average age 74
Drug cost, 2024
$6.1M
2,634 prescriptions
Company payments, 2025
$16K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pablo M Pella was code 99309 (snf e&m), 883 times for 120 patients. In total Pablo M Pella billed 2,530 services in 17 codes, and Medicare paid $189K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99309 SNF E&M | Office | 883 | 120 | $83.42 | $74K |
| 99232 Hospital E&M - Subsequent | Facility | 563 | 231 | $59.37 | $33K |
| 99231 Hospital E&M - Subsequent | Facility | 378 | 95 | $37.52 | $14K |
| 99222 Hospital E&M - Initial | Facility | 167 | 149 | $97.58 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 152 | 139 | $87.58 | $13K |
| 99214 Office E&M - Established | Office | 127 | 74 | $89.38 | $11K |
| 99308 SNF E&M | Office | 86 | 37 | $57.69 | $4,961 |
| 99306 SNF E&M | Office | 83 | 81 | $139.29 | $12K |
| 99215 Office E&M - Established | Office | 38 | 36 | $104.34 | $3,965 |
| 99204 Office E&M - New | Office | 15 | 15 | $130.52 | $1,958 |
| 99213 Office E&M - Established | Office | 13 | 13 | $59.46 | $773 |
By year: 2022 $152K for 2,072 services; 2023 $143K for 1,817 services; 2024 $189K for 2,530 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pablo M Pella prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 462 prescriptions and refills. In total Pablo M Pella wrote 2,634 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 462 | 464 | 58 | $1.8M |
| Tivicay Dolutegravir Sodium | 294 | 300 | 36 | $699K |
| Dovato Dolutegravir Sodium/Lamivudine | 253 | 269 | 31 | $772K |
| Descovy Emtricitabine/Tenofov Alafenam | 235 | 241 | 31 | $499K |
| Prezcobix Darunavir/Cobicistat | 137 | 139 | 16 | $317K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 90 | 90 | 11 | $407K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 69 | 74 | 23 | $461 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 63 | 64 | 16 | $1,308 |
| Isentress Raltegravir Potassium | 54 | 54 | Under 11 | $105K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 51 | 51 | Under 11 | $186K |
| Valacyclovir Valacyclovir Hcl | 49 | 69 | 13 | $1,328 |
| Fluconazole Generic | 46 | 49 | 13 | $803 |
| Ciprofloxacin Hcl Generic | 45 | 45 | 18 | $776 |
| Etravirine Generic | 42 | 42 | Under 11 | $46K |
| Rosuvastatin Calcium Generic | 41 | 77 | Under 11 | $329 |
Brand drugs: 1,816 claims; generic drugs: 818 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pablo M Pella $16K ($16K in general payments such as food, travel and fees) from 16 companies. The largest payer was Gilead Sciences, Inc. with $13K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 48 | $13K |
| ViiV Healthcare Company GSK | 49 | $1,299 |
| Merck Sharp & Dohme LLC MRK | 10 | $235 |
| Theratechnologies Inc. THTX | 13 | $218 |
| Abbvie Inc. ABBV | 6 | $162 |
| Insmed, Inc. INSM | 8 | $154 |
| Paratek Pharmaceuticals, Inc. | 9 | $138 |
| Shionogi Inc 4507.T | 4 | $93.15 |
| Melinta Therapeutics, LLC | 3 | $86.34 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $84.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.